Eisai Opens for Business in the Netherlands

Hatfield, England (ots/PRNewswire) - Eisai Europe
Limited, a subsidiary of Eisai Co., Ltd announces the establishment
of its sales and marketing operation in its wholly owned subsidiary
in the Netherlands based in Amsterdam. The first Eisai product on the
Dutch market is the epilepsy treatment Zonegran (zonisamide).

Commenting on the opening of the new subsidiary, Eisai
Netherlands Managing Director, Mr Gert-Jan Kouseband said: "Eisai's
entry into the Netherlands is aligned with the company's wider
strategy of establishing a solid foundation in Europe. We currently
have one product on the market and hope to have five products
available in the coming months, boosting our presence in the market.
This will allow Dutch patients access to treatments not previously
available to them and further supports Eisai's human health care
(hhc) mission to satisfy unmet medical needs and contribute to the
health and well being of people worldwide."

The Dutch company's initial area of focus is epilepsy and a
dedicated Eisai team has already been established. Zonegran, an
adjunctive treatment for adult patients with partial seizures, with
or without secondary generalisation, is now available. It is
estimated that 100,000 Dutch people suffer from epilepsy[1] and the
availability of Zonegran in the Netherlands will provide an
additional treatment option to help manage their condition. Epilepsy
is a key strategic area for Eisai in Europe and the company is
committed to developing and delivering highly beneficial new
treatments to help improve the lives of people with epilepsy.

Eisai's commitment to establish a strong European presence is
further seen by a GBP100m investment in the state-of-the art European
headquartered in Hatfield, UK, which opened in 2009. The European
Knowledge Centre acts as the hub for all of Eisai's European
operations.

Notes to Editors

About Eisai Europe in Epilepsy

Eisai is committed to making further contributions to addressing
the diversified needs and improving quality of life of patients with
epilepsy. Eisai has three currently marketed treatments in Europe,
these are:

- Zonegran(R) (zonisamide)as adjunctive therapy in adult patients with
partial-onset seizures, with or without secondary generalisation
- Zebinix(R) (eslicarbazepine acetate) (under license from Bial - Portela
& Ca, S.A in Europe) as adjunctive therapy in adult patients with
partial-onset seizures, with or without secondary generalisation
- Inovelon(R) (rufinamide) is an adjunctive treatment of seizures
associated with Lennox-Gastaut Syndrome

About Eisai

Eisai is one of the world's leading R&D-based pharmaceutical
companies, that has defined its corporate mission as "giving first
thought to patients and their families and to increasing the benefits
health care provides," which we call human health care (hhc).

Eisai concentrates its R&D activities in three key areas:

- Integrative Neuroscience: Alzheimer's disease, multiple sclerosis,
neuropathic pain, epilepsy, depression, etc
- Integrative Oncology: Anticancer therapies; tumour regression, tumour
suppression, antibodies, etc and Supportive cancer therapies; pain
relief, nausea, etc
- Vascular/Immunological Reaction: Acute coronary syndrome,
atherothrombotic disease, sepsis, rheumatoid arthritis, psoriasis,
Crohn's disease, etc

With operations in the U.S., Asia, Europe and its domestic home
market of Japan, we employ more than 10,000 people worldwide, and
reported consolidated sales of over GBP3.53 billion in FY2007, an
increase of 8.9% year on year. In Europe, Eisai undertakes sales and
marketing operations in over 20 markets, including the United
Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland,
Austria, Denmark, Finland, Norway, Portugal, Iceland, Czech Republic,
Hungary, and Slovakia.

For further information please visit our web site
http://www.eisai.co.jp

References

---------------------------------

[1] Epilepsy Institutes of the Netherlands Foundation (SEIN)
General Information Last accessed Jan 2011 http://www.sein.nl/sites/d
efault/images/algemeen/EpilepsiecentrumSEIN_Engels_ def.pdf

(Due to the length of this URL, it may be necessary to copy and
paste this hyperlink into your Internet browser's URL address field.
Remove the space if one exists.)

ots Originaltext: Eisai Europe Limited
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: Media Inquiries, Cressida Robson, Eisai Europe
Ltd.,cressida_robson@eisai.net, +44(0)7908-314-155; For further
informationplease contact: Benjamyn Tan / Helen Swift, Tonic Life
Communications,+44(0)20-7798-9262 / +44(0)20-7798-9900,
benjamyn.tan@toniclc.com /helen.swift@toniclc.com; Eisai Europe Ltd -
Cressida Robson:+44(0)845-676-5318